Erste Asset Management GmbH Invests $82,000 in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Erste Asset Management GmbH purchased a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 54,000 shares of the company’s stock, valued at approximately $82,000.

A number of other large investors also recently modified their holdings of LYEL. Intech Investment Management LLC acquired a new position in shares of Lyell Immunopharma in the third quarter valued at $52,000. Dimensional Fund Advisors LP raised its stake in shares of Lyell Immunopharma by 197.8% in the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock valued at $58,000 after purchasing an additional 26,635 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Lyell Immunopharma by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after purchasing an additional 19,287 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Lyell Immunopharma by 78.1% in the third quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock valued at $79,000 after purchasing an additional 25,247 shares in the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in shares of Lyell Immunopharma by 37.3% in the third quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company’s stock valued at $186,000 after purchasing an additional 36,715 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Bank of America lowered Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their target price for the company from $6.00 to $1.00 in a research note on Wednesday, October 30th. HC Wainwright restated a “neutral” rating and issued a $1.00 target price on shares of Lyell Immunopharma in a research note on Tuesday, November 12th.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $0.94 on Thursday. The business’s fifty day moving average price is $1.13 and its two-hundred day moving average price is $1.54. Lyell Immunopharma, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $3.26. The stock has a market capitalization of $275.24 million, a price-to-earnings ratio of -1.19 and a beta of -0.45.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.03 million for the quarter. Research analysts expect that Lyell Immunopharma, Inc. will post -0.8 EPS for the current fiscal year.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.